Paul Hislop, CEO and majority shareholder of ASX listed ZOONO Group Ltd (ZNO) confirmed at their AGM held in Sydney on 7th November 2109 that Zoono was at that cutting edge of assisting globally in the reduction of African Swine Flu outbreaks.
He advised the meeting of shareholders, and the ASX via the meetings presentation pack, that the focus was for ‘swine trials’ in Russia, Australia, Korea and China were trials are scheduled shortly with leading industry participants.
Industry commentators are speculating that ups to 25% of the global pig population could be killed by African Swine Flu and has all sectors of the the pig industry very concerned that safe eradication methods are found as soon as possible.
Swine flu is spread via contaminated objects and Zoono’s antimicrobial technology is well suited to the pig farm environment to assist stop the spread. Paul Hislop advised the meeting that early trials to date are really encouraging and referred shareholders at the AGM to the results in the following images of bacteria killed after just 10 minutes from the time Zoono was applied.
Zoono provides cost effective broad-spectrum antimicrobial protection which is effective against a wide range of disease-causing bacteria. Protection against bacteria is more important than ever as microorganisms evolve, and antibiotics become less effective.
Zoono significantly reduces the spread of harmful bacteria, viruses, fungi, mould and yeast. Their innovative technology will last up to 30 days on treated surfaces and up to 24 hours on skin. An advance manufacturing process to provide long-lasting bonding capabilities.
Zoono technology is water-based, alcohol-free and free from dangerous chemicals. To learn more about this next generation of antimicrobial technology, visit their website: https://zoono.com/
Read Related Biotech News Zoono Articles here:
Author: Tony Adams
Disclosure: The writer and immediate associates hold shares in the company.